63 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
Definitive Additional Materials
Soliciting Material under §240.14a-12
SQZ Biotechnologies Company
(Name of Registrant as Specified In Its Charter … previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
SQZ
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
Definitive Additional Materials
Soliciting Material under §240.14a-12
SQZ Biotechnologies Company
(Name of Registrant as Specified In Its Charter … previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
SQZ
8-K
EX-2.1
SQZB
SQZ Biotechnologies Co
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
, meeting minutes and strategy materials); (c) all data, results and records of all studies, including the Laboratory Studies, Non-Clinical Studies … of the SQZ Clinical Product(s) or SQZ Therapeutic Product(s), including raw materials and other supplies therefor;
all cells owned or controlled by Seller
8-K
SQZB
SQZ Biotechnologies Co
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT … SQZ AND THE PROPOSED TRANSACTION. Investors may obtain a free copy of these materials (when they are available) and other documents filed by SQZ
DEFA14A
xxvc t8a2kp
26 Apr 23
Additional proxy soliciting materials
4:31pm
PRE 14A
v4orhl7khp02ds4v2l2
10 Apr 23
Preliminary proxy
4:31pm
8-K
EX-99.1
gzuw522
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
8-K
EX-99.1
t4z0jsg4ef0cn0xu
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
8-K
EX-99.1
7e7m82lwz6e 02rzxb
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
EX-99.1
lzceg3hr7 bgvk
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
EX-99.1
lvtrh14
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm